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Abstract
Background: Mucus overproduction is a characteristic of inflammatory pulmonary diseases including
asthma, chronic bronchitis, and cystic fibrosis. Expression of two mucin genes, MUC2 and MUC5AC, and
their protein products (mucins), is modulated in certain disease states. Understanding the signaling
mechanisms that regulate the production and secretion of these major mucus components may contribute
significantly to development of effective therapies to modify their expression in inflamed airways.
Methods:  To study the differential expression of Muc2 and Muc5ac, a novel monoclonal antibody
recognizing guinea pig Muc2 and a commercially-available antibody against human MUC5AC were
optimized for recognition of specific guinea pig mucins by enzyme-linked immunosorbent assay (ELISA),
Western blot, and immunohistochemistry (IHC). These antibodies were then used to analyze expression
of Muc2 and another mucin subtype (likely Muc5ac) in guinea pig tracheal epithelial (GPTE) cells stimulated
with a mixture of pro-inflammatory cytokines [tumor necrosis factor-α (TNF-α), interleukin 1β (IL-1β),
and interferon- γ (IFN-γ)].
Results: The anti-Muc2 (C4) and anti-MUC5AC (45M1) monoclonal antibodies specifically recognized
proteins located in Muc2-dominant small intestinal and Muc5ac-dominant stomach mucosae, respectively,
in both Western and ELISA experimental protocols. IHC protocols confirmed that C4 recognizes murine
small intestine mucosal proteins while 45M1 does not react. C4 and 45M1 also stained specific epithelial
cells in guinea pig lung sections. In the resting state, Muc2 was recognized as a highly expressed intracellular
mucin in GPTE cells in vitro. Following cytokine exposure, secretion of Muc2, but not the mucin recognized
by the 45M1 antibody (likely Muc5ac), was increased from the GPTE cells, with a concomitant increase in
intracellular expression of both mucins.
Conclusion: Given the tissue specificity in IHC and the differential hybridization to high molecular weight
proteins by Western blot, we conclude that the antibodies used in this study can recognize specific mucin
subtypes in guinea pig airway epithelium and in proteins from GPTE cells. In addition, Muc2 is highly
expressed constitutively, modulated by inflammation, and secreted differentially (as compared to Muc5ac)
in GPTE cells. This finding contrasts with expression patterns in the airway epithelium of a variety of
mammalian species in which only Muc5ac predominates.
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Background
In the mammalian airway, mucus secreted by the epithe-
lium and submucosal glands provides a defensive barrier
between the outside environment and the airways. Mucus
traps, neutralizes, and eliminates inhaled irritants, pollut-
ants, and pathogens. Unfortunately, conditions that pro-
voke overexpression of gel-forming mucin glycoproteins
(the major structural components of mucus) can clog the
conducting airways, and, ultimately, impair effective gas
exchange. Many airway diseases, including asthma,
chronic bronchitis, and cystic fibrosis, exhibit mucus over-
expression [1-3]. Thus, understanding the mechanisms of
expression and secretion of airway mucins has obvious
pathophysiological significance and may assist in design-
ing novel therapeutics for asthma and other airway dis-
eases.
Airway mucins are derived from either epithelial goblet
cells or epithelial cells of the submucosal gland [4]. At
least twenty mucin genes have been reported, with expres-
sion of eight detectable in the human airway [5-9]. Four
of these genes are known to encode gel-forming mucins
(MUC2, MUC5AC, MUC5B, MUC6), while MUC19 was
recently identified as having the potential to encode a gel-
forming mucin based on its primary sequence [9]. MUC2
and MUC5AC expression are altered in inflamed airways
[10-13] and, therefore, may contribute to the pathogene-
sis of several respiratory diseases. These mucins also
exhibit cell- and tissue-specific expression in mammals
where, in addition to their airway expression, Muc2 is
expressed primarily in gastrointestinal epithelium and
Muc5ac in gastric epithelium [14,15]. Differential regula-
tion of mucin subtype expression may affect mucus com-
position in disease states, although little is known
regarding mechanisms that modulate such expression
[16-20].
The antigen-sensitized and -challenged guinea pig is an
excellent model of allergic asthma, exhibiting major hall-
marks of human asthma, including airway hyperrespon-
siveness and eosinophilic inflammation [21-24].
However, research using the guinea pig model has been
hampered by the lack of available molecular tools, espe-
cially for studying mucin subtypes. Recently, Muc2 and
Muc5ac-specific oligonucleotide probes were synthesized
based on gene sequence information available from
related mammalian species [25]. It was found that Muc2
gene expression increased with TNF-α stimulation in
GPTE cells, whereas little, if any, Muc5ac mRNA expres-
sion was measured in control or stimulated cultures.
Muc2 expression in airway epithelium is not commonly
reported in other mammalian species, whereas Muc5ac is
described frequently as the major gel-forming mucin in
the airway epithelium of humans, horses and rodents [26-
30].
The purpose of this study was to determine whether or not
Muc2 and Muc5ac subtypes are regulated differentially in
the guinea pig tracheal epithelium. A monoclonal anti-
body against Muc2 apomucin was developed for detec-
tion of guinea pig Muc2 and a commercially-available
monoclonal antibody against human MUC5AC was opti-
mized for detection of guinea pig Muc5ac. GPTE cells were
exposed to a pro-inflammatory cytokine mix of TNF-α, IL-
1β, and IFN-γ, and tested subsequently for differential
expression of Muc2 and Muc5ac. While intracellular Muc2
and Muc5ac production and mRNA expression increased
similarly, only apparent Muc2 secretion increased signifi-
cantly over constitutive levels following inflammatory
stimulation. These results demonstrate, for the first time,
that mucin subtypes are regulated differentially in guinea
pig tracheal epithelial cells, suggesting that different
mechanisms may exist for mucin subtype storage and/or
secretion.
Methods
Cell Culture
Primary cultures of differentiated GPTE cells were estab-
lished using an air-liquid interface procedure [31]. Briefly,
guinea pig tracheae were excised from euthanized ani-
mals, the epithelial cells dissociated proteolytically and
washed. Transwell inserts (Corning Costar, Cambridge,
MA) were coated with rat tail collagen type I (BD Bio-
sciences, Franklin Lake, NJ) and the cells resuspended and
seeded onto the inserts at a density of 5 × 104 cells/cm2 in
Dulbecco's modified Eagle's medium (DMEM)/F12 sup-
plemented with 5% fetal bovine serum (FBS), 4 mM L-
glutamine (Invitrogen, Carlsbad, California), 1% HL-1™
supplement, 25 ng/ml recombinant human epidermal
growth factor (Serologicals, Norcross, GA), 50 nM retinal
acetate, 100 µg/ml gentamicin, 40 U/ml nystatin (Sigma,
St. Louis, MO), and 0.5 µg/ml amphotericin-B. Cells were
cultured at 37°C in an atmosphere of 3% CO2. Medium
was renewed every other day until the cells were 70–80%
confluent (4–5 days), at which time medium was
removed from the apical surface and cultures were fed
basally with serum-free medium for an additional 7 days
to allow mucous cell differentiation. Reagents listed above
were purchased from Cambrex Corporation (East Ruther-
ford, NJ), unless otherwise noted.
The Institutional Animal Care and Use Committee of
North Carolina State University approved all protocols for
the use of animals that pertain to this study.
Production of anti-Muc2 monoclonal antibody
A 522 base pair fragment of guinea pig Muc2 cDNA, deter-
mined previously to be a coding region of the carboxy-ter-
minal cysteine-rich region of guinea pig Muc2 [25], was
cloned into a bacterial protein expression vector (pCAL-n;
Stratagene, La Jolla, CA). The insert was verified byRespiratory Research 2006, 7:35 http://respiratory-research.com/content/7/1/35
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sequencing (DNA Sequencing Facility, University of
North Carolina at Chapel Hill). The bacterial host strain
BL21(DE3)pLysS (Stratagene, La Jolla, CA) was then
transformed with the ligated vector. An overnight, ampi-
cillin-selected BL21 (DE3)pLysS culture was expanded in
Luria-Bertani broth at 37°C for 3–5 hrs with shaking. Pro-
tein expression was then induced by 1 mM isopropyl-1-
thio-β-D-galactopyranoside (IPTG; Sigma) during loga-
rithmic growth. Culture lysates of induced (+IPTG) and
uninduced (-IPTG) cells were resolved on a 10% SDS-
PAGE gel. Staining of total protein in the gel indicated
high-level induction of a ~29 kDa protein, which formed
an insoluble inclusion body. This protein fragment was
purified by elution from an electrophoresis gel, using high
concentrations of detergent to keep the inclusion body
soluble. After elution, the putative Muc2 protein fragment
was verified by SDS-PAGE and dialyzed into phosphate
buffered saline (PBS), pH 7.4.
A monoclonal antibody was raised against this purified
Muc2 protein fragment by the North Carolina State Uni-
versity Hybridoma facility. Specifically, a BALB/c mouse
was inoculated 3 times with 100 µg of purified Muc2 pro-
tein fragment mixed with Freund's Incomplete Adjuvant
over a 3 month time period. Serum from the mouse was
collected two weeks after the final inoculation.
Antibody against the recombinant Muc2 protein fragment
was detected in a 1:100 dilution of mouse serum collected
from the antigen-challenged mouse via an ELISA (proto-
col below). Results indicated the presence of an anti-Muc2
antibody in the serum as a reaction was observed in test
wells coated with 50 ng of purified Muc2 protein frag-
ment. Three additional booster injections were adminis-
tered to the mouse before antibody-producing spleen cells
were collected and hybridized with murine myeloma cells
(SP2/0-Ag14). Fused cells were diluted and plated to ~1
cell per well in eight 96-well plates and grown for two
weeks in modified RPMI 1640 medium with 10% fetal
bovine serum, 2 mM L-glutamine, 1× hypoxanthine-thy-
midine, 5 U/ml penicillin, and 5 µg/ml streptomycin at
37°C, 5% CO2. All culture reagents were purchased from
Cambrex. Thirty-seven of 768 cultures were positive for
Muc2 antibody when assayed by ELISA against purified
Muc2 protein fragment. These cultures were expanded
and retested. One clone (clone 4.68a) was selected for
best overall performance based on immunohistochemis-
try, Western blot, and ELISA testing and was used for
monoclonal selection and expansion.
Two additional rounds of small-scale expansion and
selection were performed. Media containing secreted anti-
body from each clone was screened against the purified
Muc2 protein fragment by ELISA. The hybridoma clone
that secreted the antibody with the strongest immunore-
activity (clone C4) was selected for final large-scale expan-
sion. Culture expansion was carried out in 225 cm2 flasks
(Corning Costar, Cambridge, MA) using the same media
as above, with the exception that only 5% FBS was added
in addition to 5% P388D1-derived growth supplement
(American Type Culture Collection, Manassas, VA). The
monoclonal antibody was purified using a Protein L col-
umn (Pierce, Rockford, IL) according to the manufac-
turer's instructions. Column fractions containing
antibody were verified by ELISA, desalted and resus-
pended in 50% glycerol. The purified monoclonal anti-
body was isotyped as mouse IgM using a commercially
available isotyping kit (Roche, Indianapolis, IN).
Collection of guinea pig tissues and mucus
Multiple tissues were dissected from euthanized adult,
male Hartley guinea pigs (Charles River, Stone Ridge,
NY). For paraffin-embedded sections, tissue was placed in
10.0% formaldehyde, rested overnight, and then paraffin-
embedded and sectioned.
Mucus secretions were also collected from small intestine,
stomach and tracheal tissue samples. The internal epithe-
lial surface of each tissue was exposed, rinsed repeatedly
with PBS, and then scraped with a rubber policeman to
remove mucus. Mucus was diluted (1:1) into PBS contain-
ing Complete Mini Protease Inhibitor Cocktail (Roche).
Isolated secretions were stored at -80°C.
Western blot of mucus proteins
Samples of isolated mucus secretions were solubilized in
denaturing sample buffer [32]. This buffer contains a
reducing agent reported previously to reduce thiols in the
mucin thereby destroying epitopes that react with the
45M1 antibody [33]. We have tested human mucin sam-
ples with a wide range of reducing agent concentrations,
and have found that the 45M1 antibody reacts with many
of these samples in an ELISA format, suggesting the
amount of reducing agent per amount of mucin is critical
to obtaining a reaction with the antibody. Thus, we have
included a reducing agent in our buffer, but have used
more protein (23.5 µg) for our Western analyses then
reported previously [32]. This enhances protein solubili-
zation while keeping enough epitopes intact for antibody
recognition.
Samples were then centrifuged at 10,000 rpm for 5 mins,
and loaded onto a 1.0% agarose gel using a horizontal gel
apparatus (Bio-Rad, Hercules, CA). Electrophoresis of
samples was carried out at 15 V (1.9 V/cm gel) for 18 hrs.
After the gel was equilibrated in tris/glycine buffer (Bio-
Rad) for 30 mins, proteins were transferred to a nitrocel-
lulose membrane using a semi-dry transfer apparatus
(Bio-Rad) according to the manufacturer's instructions.
The nitrocellulose membrane was washed in PBS andRespiratory Research 2006, 7:35 http://respiratory-research.com/content/7/1/35
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then blocked with 3% powdered milk in PBS. The mem-
brane was hybridized with primary antibody (newly
developed C4 or 45M1 from Lab Vision, Fremont, CA), at
stated dilutions, in 1% milk at 4°C overnight. After wash-
ing the nitrocellulose membrane in PBS, the membrane
was incubated with horseradish peroxidase (HRP)-conju-
gated goat anti-mouse antibody (MP Biomedicals, Irvine,
CA) diluted 1:2000 in 1% milk. The membrane was then
washed in PBS, washed additionally in PBS + 0.05%
Tween-20, and finally rinsed with water. An ECL™ chemi-
luminescent detection kit (Amersham Biosciences, Piscat-
away, NJ) was used for visualization.
Enzyme linked immunosorbent assay (ELISA)
A 96-well high-binding ELISA plate (Corning Costar) was
coated with experimental samples at 4°C overnight. The
plate was then washed twice with PBS. Wells were blocked
with a solution of 3% cold-water fish gelatin (Sigma) in
PBS for two hrs at room temperature. Following two
washes with PBS, samples were exposed to the primary
antibody (newly developed C4 or 45M1) diluted as indi-
cated in 0.3% cold-water fish gelatin for 1 hr at room tem-
perature. The plate was washed three times, labeled with a
HRP-conjugated goat anti-mouse IgG (MP Biomedicals,
Irvine, CA) diluted 1:2000 in 0.3% cold-water fish gelatin,
and incubated for 1 hr at room temperature. After second-
ary antibody incubation, the plate was washed with PBS,
and the color developed for 5 mins to 3 hrs, depending on
primary antibody concentration and immunoreactivity. A
1M H2SO4 solution was then added to halt color develop-
ment and absorbance was read at 450 nm.
Immunohistochemistry
Paraffin-embedded sections of guinea pig liver and tra-
chea were immunostained by the Histopathology Labora-
tory at the North Carolina State University, College of
Veterinary Medicine. Sections of guinea pig lung tissue
were provided by Dr. Allison Fryer of Oregon Health and
Science University (Portland, OR) and were stained in our
laboratory. Briefly, sections were deparaffinized in xylene,
rehydrated through a series of graded ethanol solutions,
rinsed with deionized water and endogenous peroxidase
activity was blocked by a 10 min immersion in methanol
containing 3% H2O2. After rinsing with ice-cold deion-
ized water and then PBS, sections were blocked with nor-
mal goat serum for 20–30 mins., followed by application
of primary antibody (C4 to detect Muc2 and 45M1 to
detect Muc5ac) for 30 mins. A 1:50 dilution of C4, or a
1:100 dilution of 45M1, was used. Sections were rinsed
with PBS and incubated with biotin-labeled goat anti-
mouse antibody (Vector Labs, Burlingame, CA) for 20–30
mins. Sections were rinsed again with PBS, and incubated
with streptavidin peroxidase complex for 10–20 mins.
Sections were then rinsed with PBS, developed with 3,
3'diaminobenzidinetetrahydrochloride (DAB), and coun-
terstained with hematoxylin. Sections were rinsed for 5
mins under tap water, dehydrated through a graded etha-
nol series and cleared with xylene prior to mounting. Neg-
ative controls were performed by substituting PBS for
primary antibody.
Real-time reverse transcriptase polymerase chain reaction 
(RT-PCR)
Total RNA was isolated from lysates of GPTE cells using
the RNeasy Mini Kit (Qiagen, Valencia, CA) according to
the manufacturer's instructions. Each sample was treated
with RNase-free DNase for 15 mins to reduce DNA con-
tamination. RNA with A260/A280 ratio of 1.95 or greater
was used for reverse transcription. 1 µg of RNA from each
sample was reverse transcribed in a 20 µl reaction using
iScript cDNA synthesis kit (Bio-Rad) according to recom-
mended conditions. 0.5 µl of each reverse-transcribed
sample was added to 1× iQ SYBR Green Supermix (Bio-
Rad), 200 nM of forward and reverse primers, and nucle-
ase-free water to a 25 µl final reaction volume. Primer
sequences and cycling conditions for Muc2, Muc5ac, and
γ-actin were as described previously [25]. Amplifications
were performed on an iCycler iQ Real-Time PCR Detec-
tion System (Bio-Rad). The starting amount of cDNA tem-
plate was extrapolated from amplification curves by the
method of Peirson [34]. Values reported are normalized
to γ-actin levels and expressed as percentage of control.
Melt-curve analysis was performed to verify that only a
single product was amplified in each reaction.
Exposure of guinea pig tracheal epithelial cells to cytomix
On day 7 after GPTE cell cultures were exposed to air,
secreted mucus was removed from the apical surface with
two washes (1× PBS). The basal media was changed and
the cultures incubated at 37°C, 3% CO2 for 12 hrs at
which time the secreted apical mucus was collected with a
single PBS wash (0.5 ml). Mucins in these collections were
measured by ELISA (see above) to determine BASELINE
values for each culture. Basal media was again changed to
begin the EXPERIMENTAL protocol. The EXPERIMENTAL
protocol spanned an additional 12 hrs, during which time
a pro-inflammatory cytokine mixture, "cytomix" (10 ng/
ml each of TNF-α, IL-1β, and IFN-γ), was added to the cul-
ture media at 0, 4, and 8 hrs after EXPERIMENTAL time
zero. In addition, control cultures were exposed to media
only for the 12-hr EXPERIMENTAL period to allow meas-
urement of CONSTITUTIVE mucus secretion. After the
EXPERIMENTAL exposure period, mucus secretions were
collected with a 0.5 ml PBS wash. BASELINE, EXPERI-
MENTAL and CONSTITUTIVE mucin samples for each
culture well were assayed in duplicate on the same 96-well
ELISA plate to minimize interplate variability. Undiluted
mucus samples were always used in the ELISA unless oth-
erwise noted. Normalized values were calculated by divid-
ing the absorbance reading corresponding to mucinRespiratory Research 2006, 7:35 http://respiratory-research.com/content/7/1/35
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secreted for the EXPERIMENTAL period by the absorbance
reading corresponding to mucin secreted during the
BASELINE period, allowing each well to serve as its own
control. Final EXPERIMENTAL/BASELINE results were
expressed as a percentage of normalized CONSTITUTIVE
mucin production for the 12-hr EXPERIMENTAL period.
All mucin samples collected from GPTE cell cultures,
unless otherwise noted, were treated with neuraminidase
enzyme originating from Arthrobacter ureafaciens (Calbio-
chem, La Jolla, CA) by a method described previously
[35].
Statistical analysis
Experimental data were analyzed for significance using
paired Student's t test or ANOVA with Tukey's post-test
comparisons, where appropriate. Differences between
treatments were considered significant at p < 0.05. Data
are represented as mean ± standard error of the mean
(SEM).
Results
C4 monoclonal antibody recognizes Muc2
To verify that the novel monoclonal antibody (C4) devel-
oped in this study would recognize guinea pig Muc2 apo-
mucin, a dilution series of purified Muc2 protein
fragment was examined by ELISA. C4 bound as little as 50
ng per test well, and absorbance values increased in a con-
centration-dependent manner (Fig. 1).
Given that C4 readily recognizes a Muc2 apomucin
epitope, the ability of this antibody to recognize Muc2
was further tested by probing the mucin-rich mucosae of
the small intestine using IHC. In mice, the small intestine
is known to express a large amount of Muc2 while Muc5ac
is not normally detected [15,36]. In mouse tissue sections,
C4 stained the epithelial lining of the small intestine (Fig.
2a). Negative controls (C4 antibody on guinea pig liver;
serum substitution for primary antibody on mouse intes-
tine) showed no staining (data not shown). Thus, the C4
antibody appears to selectively recognize protein within
tissues known to express large amounts of Muc2, such as
the murine small intestine.
Western blot analysis was then used to verify specificity of
the C4 antibody. C4 hybridized to mucus from the guinea
pig small intestine but not from stomach (Fig. 2b). Specif-
ically, the C4 antibody labeled two discernable bands:
one fast mobility band and an intense, slower mobility
band or smear. This dual banding pattern is similar to that
described by Axelsson et al. [37] for mucus obtained from
a colon adenocarcinoma cell line and immunoprecitiated
with MUC2-specific antibodies. In that study, a faster
mobility band was described as the MUC2 monomer,
whereas a slower mobility band was thought to consist of
MUC2 oligomers resistant to reduction treatment, a find-
ing confirmed elsewhere [38].
To expand the utility of the C4 antibody for relative quan-
titation of specific mucins, we established conditions for
its use in a more sensitive ELISA. C4 antibody bound
mucus isolated from both guinea pig small intestine and
stomach by ELISA (Fig. 2c), but at a 1:500 dilution of this
antibody (0.8 µg/ml) small intestinal mucus was recog-
nized selectively. Thus, we chose to use this dilution for all
subsequent ELISAs, as it appeared to allow greater differ-
ential recognition of Muc2.
45M1 monoclonal antibody recognizes Muc5ac in guinea 
pig tissue
To examine expression of Muc2 versus Muc5ac in guinea
pig tissues, we developed guinea pig-specific assays using
45M1 (Lab Vision), a commercially-available antibody
known to recognize Muc5ac in tissues from human, mon-
key, rat, rabbit, pig, and chicken [33,39]. Although Muc2
was detected in murine small intestinal tissue (Fig. 2a), a
nearby section from this same tissue showed only mini-
mal reaction to 45M1 (Fig. 3a). Negligible, non-specific
labeling was observed when the 45M1 antibody was
reacted to sections of guinea pig liver or when tissue sec-
tions were reacted with control mouse sera in place of the
primary antibody (data not shown).
To further verify that the 45M1 monoclonal antibody
could recognize Muc5ac from guinea pig with specificity,
Anti-Muc2 monoclonal antibody (C4) binds to Muc2 apomu- cin in ELISA Figure 1
Anti-Muc2 monoclonal antibody (C4) binds to Muc2 
apomucin in ELISA. Guinea pig Muc2 apomucin fragment 
(10, 50, 100, and 200 ng/well) purified from transformed bac-
terial culture lysate was measured by ELISA using purified C4 
monoclonal antibody (400 µg/ml), diluted 1:100 in 0.3% cold-
water fish gelatin. Results indicate the C4 monoclonal anti-
body binds to the Muc2 apomucin fragment in a concentra-
tion-dependent manner. Absorbance values read at 450 nm 
are shown corrected for background. Each sample was meas-
ured in triplicate, and data are shown as mean ± SEM. This 
assay was repeated three times with similar results.Respiratory Research 2006, 7:35 http://respiratory-research.com/content/7/1/35
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the antibody was hybridized to Western blots containing
mucus from guinea pig stomach and small intestine (Fig.
3b). As anticipated, 45M1 recognized only the stomach
sample. Specifically, a 1:5000 dilution of the 45M1 anti-
body labeled a smeared, high molecular weight band.
This band was similar to those observed in Western blots
containing respiratory secretions from normal or chronic
bronchitic subjects [40] or samples of mucus secreted
from cell lines of human mucosal origin [32]. Antibodies
used in these earlier experiments were raised against pep-
tide sequences corresponding to portions of MUC5AC;
specifically, RNQDQQGPFKMC [40] or WFDVDFPSPG-
PHGGDKETYNNI [32].
Using 45M1 in an ELISA, a 1:1000 or 1:100 dilution of the
antibody recognized 5.8 µg of total stomach mucus per
well (Fig. 3c). The same dilutions of 45M1, however, did
not bind to wells coated with an equal amount of total
protein isolated from the small intestinal mucosa.
C4 and 45M1 antibodies recognize specific cells in the 
guinea pig airway epithelium
To determine whether the C4 and 45M1 antibodies could
recognize proteins in the guinea pig lung in vivo, we sub-
jected sections from guinea pig lung to immunohisto-
chemistry employing these antibodies. Both antibodies
recognized specific cells in the airway epithelium with lit-
tle to no staining observed in underlying airway cells,
nearby endothelium or in the alveolar regions (Fig. 4).
Thus, these findings suggest the guinea pig airway epithe-
lium expresses abundant Muc2 (Fig. 4, left panel) and
Muc5ac (Fig. 4, right panel).
Neuraminidase treatment improves 45M1 performance in 
ELISA
Both the anti-Muc2 (C4) and the 45M1 antibodies are
thought to preferentially recognize core mucin proteins.
Since mucin populations isolated from lung are known to
be heavily O-glycosylated [40,41], it is sometimes possi-
ble to enhance the specific performance of mucin-recog-
nizing antibodies by removing carbohydrate moieties that
obscure the protein backbones [35]. Neuraminidase, an
enzyme that cleaves neuraminic acid carbohydrate groups
from mucin glycoproteins [35], was used to determine
whether recognition by the C4 or 45M1 antibodies could
be enhanced in our ELISA method. Serially diluted sam-
ples of secreted mucus from GPTE cells, with and without
neuraminidase treatment, were subjected to ELISAs using
both mucin subtype monoclonal antibodies (Fig. 5). Neu-
raminidase treatment had minimal impact on C4 per-
formance in ELISA (Fig. 5a), with both treated and non-
treated curves having similar slope and R2-fit. Neuramini-
dase treatment had a greater impact on 45M1 ELISA per-
formance (Fig. 5b), extending the linear range to higher
concentrations. Without treatment, the 45M1 antibody
recognized a linear relationship of protein concentration
to absorbance for total mucus concentrations to 35 ng/
well. With neuraminidase treatment, consistent increases
in absorbance corresponding to increased mucus concen-
tration were observed over the range of 0.07 to 280 ng/
C4 antibody recognizes small intestinal mucus preferentially  by immunohistochemistry, Western blot, and ELISA Figure 2
C4 antibody recognizes small intestinal mucus pref-
erentially by immunohistochemistry, Western blot, 
and ELISA. a) Immunohistochemistry. The C4 anti-
body (diluted 1:50) recognizes the epithelial lining of fetal 
mouse small intestine by immunohistochemistry. Note dark 
brown staining of specific cells. Magnification using 40× 
objective. b) Western blot hybridized with the C4 
antibody. 23.4 µg of mucus collected from either the guinea 
pig small intestine (I) or stomach (S) was subjected to elec-
trophoresis through a 1.0% agarose gel and then transferred 
to a nitrocellulose membrane. Hybridization with the C4 
antibody (1:100) labeled a high molecular weight smear and a 
second high molecular weight band in the intestinal mucus, 
but did not recognize the stomach mucus. Western blot 
shown is representative of three separate blots. c) ELISA 
plate was coated with equal amounts of guinea pig stomach 
or small intestinal mucus (11.7 µg per well). The C4 antibody 
(1:500) preferentially recognizes the small intestinal mucus, 
although less differentiation is observed at lower working 
concentrations of the antibody. Each sample was assayed in 
triplicate, and data are shown as mean ± SEM. The assay was 
done twice using two independent sample isolations, with 
similar results obtained each time.Respiratory Research 2006, 7:35 http://respiratory-research.com/content/7/1/35
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well. Based on these findings, all mucin collected from
GPTE cells was subjected to neuraminidase treatment
prior to ELISA to avoid potential underestimation of the
amount of Muc5ac.
Muc2 and Muc5ac are differentially secreted from GPTE 
cells
Finally, we sought to determine whether specific mucin
subtypes were expressed differentially in GPTE cells. To
examine constitutive Muc2 and Muc5ac secretion versus
intracellular expression, equal amounts of total protein
derived from extracellular secretions or intracellular
lysates were quantified for both mucin subtypes by ELISA
(Fig. 6a). The relative amounts of Muc2 and Muc5ac glyc-
oproteins cannot be determined directly by this approach
due to lack of a coordinated mucin standard for use in
both the Muc2 and Muc5ac ELISAs, and because of poten-
tial differences in assay kinetics of the subtype-specific
antibodies. Therefore, the ratio of intracellular to secreted
mucin for each subtype was examined, with this ratio
greater for Muc2 than for Muc5ac. This suggests that less
Muc2 than Muc5ac is secreted under constitutive circum-
stances, leaving Muc2 stores within the cells.
To determine if expression of the mucin subtypes can be
modulated differentially in response to inflammation,
GPTE cells were exposed to a mixture of pro-inflammatory
cytokines (TNF-α, IL-1β, and IFN-γ or "cytomix") for 4
hrs. This exposure was carried out after a baseline mucus
collection and a subsequent 8-hr rest period. Arbitrarily
setting the level of constitutive mucin secretion (media
only) for each subtype at 100%, secretion of Muc2
increased more than 100% over constitutive levels follow-
ing cytokine stimulation, while no significant change in
Muc5ac secretion was observed (Fig. 6b). In contrast, after
setting the constitutive intracellular amount of Muc2 and
Muc5ac (media only) at 100%, intracellular production of
both mucin subtypes increased similarly following
cytokine exposure, showing a 50% elevation over consti-
tutive levels (Fig. 6c). These findings suggest inflamma-
tion may induce release of pre-formed Muc2 from GPTE
cells, while at the same time stimulating the cells to
increase intracellular mucin stores of both Muc2 and
Muc5ac.
Muc2 and Muc5ac gene expression changes with cytokine 
exposure
To determine if Muc2 and Muc5ac gene expression pat-
terns correlate with mucin protein expression following
exposure to pro-inflammatory cytokines, GPTE cells were
exposed to cytomix over a time course of 0 to 12 hrs and
total RNA was extracted from the cells. There appeared to
be an overall trend toward an increase in steady-state lev-
els of both Muc2 and Muc5ac mRNAs by 8 hrs of exposure
(Fig. 6d); however, this increase was not statistically sig-
nificant (p > 0.05 by ANOVA) due to variability between
cultures. By contrast, at the earlier 4-hr time point,
cytokine exposure induced a significant increase in Muc2
mRNA when compared to Muc5ac mRNA; Muc5ac mRNA
remained at pre-exposure levels. Thus, while the increase
45M1 antibody recognizes stomach mucus preferentially by  Western blot, and ELISA Figure 3
45M1 antibody recognizes stomach mucus preferen-
tially by Western blot, and ELISA. a) Immunohisto-
chemistry. The 45M1 antibody (diluted 1:100) does not 
recognize the majority of the cells lining a section of fetal 
mouse small intestine. Magnification using 40× objective. b) 
Western blot hybridized with the C4 antibody. 23.4 
µg of mucus collected from either guinea pig small intestine 
(I) or stomach (S) was subjected to electrophoresis through 
a 1.0% agarose gel and then transferred to a nitrocellulose 
membrane. Hybridization with the 45M1 antibody labeled 
high molecular weight protein in stomach mucus, with no 
labeling evident for small intestinal mucus. Western blot 
shown is representative of three separate blots. c) ELISA 
wells were coated with 5.8 µg of guinea pig stomach or small 
intestinal mucus. 45M1 (1:100 and 1:1000) recognized stom-
ach mucus, but not small intestinal mucus. Each sample was 
assayed in triplicate and data are shown as mean ± SEM. The 
assay was done twice using two independent sample isola-
tions, with similar results obtained each time.Respiratory Research 2006, 7:35 http://respiratory-research.com/content/7/1/35
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in both mRNAs was ultimately similar, induction of
Muc5ac gene expression seemed to lag behind that of
Muc2. It may be that the early increase in Muc2 mRNA is
a secondary consequence of the cytomix-induced prefer-
ential secretion of stored Muc2, rather than a direct induc-
tion of Muc2 transcription by the cytokines. These results
suggest that exposure to pro-inflammatory cytokines can
induce an increase in Muc2 gene expression in GPTE cells,
with some increase in Muc5ac mRNA also possible with
extended exposure. Such increases in gene expression
could play a role in regulating the cumulative increase in
intracellular Muc2 and Muc5ac observed in these cells fol-
lowing exposure to pro-inflammatory cytokines (Fig. 6c).
Discussion
In this study, we have continued to develop molecular
tools applicable to the study of mucus production in a
guinea pig model, particularly targeting mucin protein
expression. Specifically, we report the successful creation
of a monoclonal antibody to guinea pig Muc2 (C4). In
addition, we have optimized a commercially available
anti-human MUC5AC monoclonal antibody (45M1) for
detection of mucin, likely Muc5ac, from guinea pig. These
antibodies have been employed to examine the expres-
sion of guinea pig Muc2 and Muc5ac during constitutive
secretion from airway epithelial cells and following expo-
sure of these cells to inflammatory cytokines. The discov-
ery that the differential expression of two mucins can be
readily measured opens avenues to molecular mechanistic
studies which could not be done using previously
reported anti-guinea pig mucin antibodies which most
likely target the extensive, non-specific carbohydrate moi-
eties on multiple mucin types [42].
Mucin specificity of each monoclonal antibody was exam-
ined using ELISA, Western blot, and IHC. Previous exper-
imentation with 45M1 has led to its acceptance as
MUC5AC-specific [36,43,44]; however, further proof was
needed to establish the C4 monoclonal antibody as spe-
cific for Muc2. We therefore determined whether C4 and
45M1 exhibitted differential staining in mucous cell-con-
taining tissues, and whether C4 could distinguish differ-
entially between sections from murine small intestine and
stomach. It has been established that secretions from
these tissues are Muc2 and Muc5ac-dominant, respec-
tively [15].
By immunohistochemistry, the C4 antibody recognized
the content of specific cells within the murine intestinal
epithelium (Fig. 2a), while the 45M1 antibody did not
stain similarly in nearby sections from the same tissue
(Fig. 3a). Additionally, no C4 staining was observed out-
side of the epithelial layer (Fig. 2a). Since the intestinal
epithelium is rich in Muc2, and the C4 antibody was
raised against a peptide expressed from a portion of the
guinea pig Muc2 cDNA, the antibody is likely recognizing
Muc2 in this tissue while the 45M1 antibody is not. The
antibodies were also found to hybridize differentially to
Western blots containing mucus secretions from guinea
pig intestinal and stomach tissue (Figs. 2b and 3b). Secre-
tions from guinea pig intestinal and stomach tissue were
also separated by electrophoresis and then transferred to
duplicate Western blots which were hybridized to either
the C4 or the 45M1 antibodies. These antibodies hybrid-
ized differentially, with the C4 antibody hybridizing to
very high molecular weight proteins in the intestinal
secretions while the 45M1 antibody hybridized to large
proteins in the stomach secretions that were a different
size than the observed C4-reactive bands. Thus, as the
intestine is known to be Muc2-rich and the stomach is
Muc5ac-rich, we conclude that the C4 antibody and the
45M1 antibody are recognizing different mucins, likely
Muc2 and Muc5ac, respectively. A similar pattern of spe-
cificity was also observed in ELISAs, with the anti-Muc2
antibody (C4) preferentially recognizing secretions from
intestine, while the 45M1 antibody preferentially recog-
nized stomach secretions. Both antibodies were found to
label specific cells within the airway epithelium of guinea
pig lung tissue, with little to no staining in underlying
cells, endothelium or alveolar tissue (Fig. 4).
Taken together, these results indicate the two antibodies
recognize different mucins, and that it is likely the C4
antibody recognizes Muc2 due, in part, to the manner in
which the antibody was generated. Although we have not
proven definitively that 45M1 recognizes Muc5ac, it does
recognize a mucin abundant in airway epithelium and
stomach tissue that is different in size from the mucin rec-
ognized by C4 (Figs. 3b and 4).
Specific cells in the guinea pig airway epithelium are recog- nized by C4 and 45M1 antibodies Figure 4
Specific cells in the guinea pig airway epithelium are 
recognized by C4 and 45M1 antibodies. IHC of guinea 
pig lung sections incubated with C4 (1:50; left panels) or 
45M1 (1:100; right panels) antibodies. Insets are higher mag-
nifications (400×) of the areas indicated by the squares in the 
reference micrographs (100× magnification). Note the dis-
tinctive staining of specific epithelial cells (dark brown) and 
the lack of staining in underlying cells and surrounding alveo-
lar regions.Respiratory Research 2006, 7:35 http://respiratory-research.com/content/7/1/35
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Use of the C4 and 45M1 antibodies has now provided the
first complete picture of Muc2 and Muc5ac production
and secretion in guinea pig airway epithelial cells. Kondo
et al. have previously demonstrated intracellular Muc5ac
protein production in differentiated guinea pig tracheal
epithelial cells in vitro [45]. Additionally, we have previ-
ously examined expression of the mRNAs corresponding
to these two mucins in guinea pig [25], determining that
the Muc2 message predominates over the Muc5ac mes-
sage in RNA isolated from GPTE cells. Data from our cur-
rent study indicate that Muc2 and Muc5ac are present at
the extracellular, intracellular, and mRNA levels in GPTE
cells. Although it is difficult to ascertain relative amounts
of Muc2 and Muc5ac glycoproteins due to differences in
assay kinetics and lack of coordinated mucin standards,
examination of the ratio of intracellular to extracellular
mucin for each of the mucin subtypes is informative.
When cells are growing without exposure to cytokines,
Muc2 is detected as an abundant intracellular reserve with
less Muc2 secreted constitutively; this is in contrast to
Muc5ac which is detected in similar intracellular and
extracellular amounts in such cells. Immunohistochemis-
try of lung tissue further supports the abundant presence
of both Muc2 and Muc5ac within airway epithelial cells in
the guinea pig.
There also appears to be a differential mucin response to
pro-inflammatory mediators (TNFα, IL-1β, and IFNγ) in
GPTE cells, with these cytokines stimulating an apparent
increase in secreted Muc2, without a detectable increase in
secreted Muc5ac. Interestingly, TNFα and IL1-β are known
to each increase mucin secretion from airway epithelial
cells independently [46,47], while INF-γ has been shown
to have an inhibitory effect on mucus stimulation in mice
[48]. Even though INF-γ and TNFα /IL1-β have counter-
regulatory effects, these proteins are nevertheless all found
in inflamed airways [49], and have been shown to collec-
tively upregulate iNOS expression [50] which has been
shown to upregulate mucin secretion [51]. Thus, while
attempting to better mimic the complex inflammatory
milieu found in a chronically-inflamed airway, we have
found that this mixture of cytokines does modulate Muc2
secretion. Future studies will be needed to determine the
contribution of the specific cytokines to the modulation
of mucin expression in GPTE cells.
While we readily detected Muc2 in guinea pig tissue and
GPTE cells, other studies examining mucin expression in
bronchial or tracheal tissue, or epithelial cells from these
tissues, in rat, mouse, horse or humans portray Muc5ac
and/or Muc5b as the dominantly-expressed mucins both
in healthy and in altered airways. In these studies, Muc2 is
often detected minimally, or not at all [26,29,40,52-54].
One explanation for the lack of detection of Muc2 in air-
way secretions has been that it is insoluble [37,38,55].
Since neuraminidase had little affect on the ability of C4
to recognize Muc2 in our study (Fig. 5a), this might sug-
gest the C4 antibody can detect O-glycosylated and non-
glycosylated Muc2 similarly; however, this interpretation
does not fully take into account the differential solubili-
ties of these two mucin forms. Thus, the apparent increase
in cytokine-induced Muc2 secretion might be due to a
greater abundance of the more soluble, O-glycosylated
Muc2 being secreted. A change in post-transcriptional
processing of MUC2 has been noted in inflamed colonic
mucosa from patients with Crohn's disease or ulcerative
colitis. In that study, the inflammation-associated altera-
tion in post-transcriptional modification of MUC2
yielded molecules with decreased sulphation whose pres-
ence was correlated to increased reaction with an anti-
MUC2 antibody [56].
Thus, the finding that intracellular Muc2 is readily detect-
able in guinea pig tracheal epithelial cells, both constitu-
tively and following exposure to pro-inflammatory
cytokines, is novel. Furthermore, while Muc2 mRNA is
already known to be enhanced by exposure to TNFα [25],
our findings provide the first example of increased Muc2
secretion in GPTE cells in response to inflammatory stim-
uli. This high level constitutive and inducible Muc2
expression in guinea pig may vary from that observed in
Neuraminidase treatment enhances 45M1 performance in  ELISA Figure 5
Neuraminidase treatment enhances 45M1 perform-
ance in ELISA. Mucin secretions were collected from 
GPTE cell cultures on day 9 after exposure to air. Samples 
were treated with neuraminidase (0.625 mU/µg total pro-
tein) for 2 hrs at 37°C [35]. Both neuraminidase-treated and 
untreated samples were diluted 2-fold in series, then coated 
on ELISA plates in duplicate. a) Neuraminidase treatment 
slightly increased absorbance values using C4 antibody 
(diluted 1:500), although the logarithmic slope and trend line 
fit of both treated and non-treated samples remained similar. 
b) Neuraminidase treatment improved the linear range of 
protein detection in an ELISA using the 45M1 monoclonal 
antibody (diluted 1:1000), as indicated by better R2 value fit 
(calculated for ranges of increasing absorbance with increas-
ing concentration) of the logarithmic trend line. Specifically, 
treatment extended the linear detection range above 35 ng/
well.Respiratory Research 2006, 7:35 http://respiratory-research.com/content/7/1/35
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Muc2, but not Muc5ac, secretion increases with pro-inflammatory stimulation in GPTE cells Figure 6
Muc2, but not Muc5ac, secretion increases with pro-inflammatory stimulation in GPTE cells. a) Total protein concentration of pooled 
samples of mucin collected from the apical surface or as intracellular lysates of non-stimulated GPTE cell cultures was determined using the Bradford 
assay. Equal amounts of protein were used to coat ELISA wells (76 ng/well), and then the presence of Muc2 or Muc5ac was examined. Results indicate 
that, in unstimulated GPTE cells, there is a higher ratio of intracellular to secreted Muc2 when compared to the ratio of intracellular to secreted 
Muc5ac. Samples from six cultures were pooled. Error bars represent assay variance of triplicate measurements. b) GPTE cells were exposed to air for 
7 days during which time goblet cell differentiation occurred and mucus secretion began. Apical surfaces were washed, media changed, and then col-
lected for secreted mucus baseline after 12 hrs incubation at 37°C, 5% CO2. Media was then changed and cultures were rested for 8 hrs and exposed to 
cytomix for 4 additional hrs. Relative amounts of Muc2 or Muc5ac in experimental and baseline collections were determined by ELISA. Experimental 
absorbance values were then corrected with baseline values, allowing each well to serve as its own control. These normalized values are expressed as a 
percentage of CONSTITUTIVE secretion observed during the 12-hr rest/exposure period, with the amount of Muc2 or Muc5ac secreted in cultures 
exposed only to media arbitrarily set at 100% of constitutive secretion. Results indicate Muc2 secretion is augmented by cytomix exposure, while 
Muc5ac secretion is equivalent in cytomix-treated and media-exposed (control) cultures. n = 5 in each group. ** = Significant change from constitutive 
mucin secretion by Student's t-test (p < 0.05). c) GPTE cells were exposed to cytomix or media (as a control) for 4 hrs. Then cells were lysed and 
assayed for intracellular mucin. The amount of Muc2 or Muc5ac in intracellular lysates from cells exposed only to media was arbitrarily set at 100%. In 
intracellular lysates from cells exposed to cytomix, both Muc2 and Muc5ac production was increased 50% over CONSTITUTIVE mucin levels. Subse-
quent time points (8 or 12 hrs exposure) showed a return to constitutive intracellular levels (data not shown). n = 6 in each group. * = Significant change 
from constitutive mucin production by Student's t-test (p < 0.01). d) GPTE cultures were exposed to 4, 8, and 12 hrs of cytomix. Total RNA was col-
lected and Muc2 and Muc5ac transcript levels were determined using real-time RT-PCR. At 4 hrs, Muc2 mRNA levels were significantly increased when 
compared to constitutive expression. A trend toward an increase in both Muc2 and Muc5ac mRNA levels following cytomix exposure when compared 
to constitutive expression was observed at later time points. n = 4–6 in each group. * = Significant change from constitutive mucin production by Stu-
dent's t-test (p < 0.05). All data points are presented as mean ± SEM.Respiratory Research 2006, 7:35 http://respiratory-research.com/content/7/1/35
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other mammalian species, including humans. It is addi-
tionally possible that different mucins respond to airway
inflammation differently depending on the species. Such
a possibility suggests the need to fully characterize which
mucins respond maximally to inflammatory stimuli when
a new animal model of mucus hypersecretion is being
developed.
Regulatory mechanisms governing differential expression
of specific mucin subtypes can exist at transcriptional and/
or translational levels. It has been shown, for example,
that inflammatory stimulation can augment the MUC5AC
message while MUC5B levels remain unchanged in the
human airway-derived cell lines A549 and NCI-H292
[52]. One mechanism by which MUC5AC expression can
be upregulated involves modulation of mRNA stability.
Such regulation has been demonstrated in A549 and nor-
mal human bronchial epithelial (NHBE) cell cultures,
where the inflammation-associated protease, neutrophil
elastase, induced an increase in MUC5AC message stabil-
ity [57] via a signaling mechanism involving secondary
production of reactive oxygen species (ROS) [13]. Tran-
scriptional regulation of MUC5AC has also been demon-
strated in epithelial cell lines, where ROS-dependent
activation of an AP-1 response element upstream of the
MUC5AC gene occurs after cigarette smoke exposure [58].
In addition, MUC2 transcripts have been observed in both
mucin-expressing and non-expressing cells [59], suggest-
ing regulation of MUC2 expression can also occur at the
level of protein translation. In our study, we observe yet
another potential level of differential mucin regulation by
detecting an increase in apparent Muc2 secretion induced
by cytokine stimulation, while the level of secreted
Muc5ac remains unchanged. This apparent differential
secretion occurs even though cytokine-induced effects on
the intracellular protein production and the long-term
mRNA levels of the two mucin subtypes do not appear to
be regulated differentially. This finding supports the the-
ory that mucin subtypes may be secreted differentially as
a form of post-translational regulation. Alternatively,
post-translational modification of mucins may be differ-
entially regulated. Thus, the increased reaction of secreted
Muc2 with the C4 antibody could be due to a cytokine-
induced change in Muc2 glycosylation, while no such
change in Muc5ac occurs.
Evidence from previous studies has demonstrated that
mucin secretion occurs through coordinated cycles of
phosphorylation/dephosphorylation of the PKC-sub-
strate, MARCKS [60], in a mechanism which induces
mucin granule movement toward the plasma membranes.
Assuming this pathway is non-selective for a particular
mucin subtype, the mucin granules themselves may be
packaged differentially with regard to mucin subtypes.
While differential secretion of specific mucin subtypes in
the absence of differential transcriptional or translational
control has not been reported previously, it has been sug-
gested that different mucin granules within a single goblet
cell may contain structurally distinct mucin subpopula-
tions [61]. The differential regulation of mucin secretion
from such mucin-specific granules in response to pro-
inflammatory stimuli might be an important mechanism
whereby the properties of airway mucus can be altered.
Such property changes could provide greater protection to
the underlying epithelial cells, but might also result in del-
eterious effects on lung function with prolonged airway
inflammation.
In summary, we have used newly developed molecular
tools to examine expression of Muc2 and Muc5ac in
mucus collected from guinea pig tissues and GPTE cells.
Specifically, a novel mouse monoclonal antibody was
raised against guinea pig Muc2 apomucin, and it, along
with a commercially-available antibody to MUC5AC,
were optimized for specific recognition of mucin from
guinea pig by ELISA, Western blot, and IHC. Using GPTE
cells, it was found that pro-inflammatory stimulation
with a cytokine mixture of TNF-α, IL-1β, and IFN-γ, stim-
ulated increased secretion of Muc2, but not Muc5ac, while
intracellular protein and long-term mRNA expression
increased similarly for both mucin subtypes. These find-
ings highlight differences in regulation of specific mucins
within the same organism, as well as suggest comparative
differences with regard to which mucins are highly
expressed, normally and in disease, among a variety of
mammalian species. This differential regulation associ-
ated with inflamed airways may well influence the
mucosal makeup, and, ultimately, the physical properties
of airway mucus in a manner that could affect clearance
and gas exchange deleteriously.
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